Aclaris submits MAA for dermatology candidate A-101

Aclaris Therapeutics Inc. (NASDAQ:ACRS) submitted an MAA under the EU decentralized procedure, with Sweden as the reference member state, for A-101 to treat seborrheic keratosis (SK). An NDA for A-101 is under FDA review with a Dec. 24 PDUFA date...